4.3Ro
From$149/mo
Source: Ro pricing page · Checked
Checked · confirm at checkout
Visit Partner link
Pricing and what is included
Sesame separates the care subscription from the prescription bill. Its official Success by Sesame page advertises the lowest care rate as $59 per month with an annual subscription. It lists the month-to-month plan at $99 and says that plan is billed every 28 days; three-, six-, and twelve-month commitments are billed in advance on their respective schedules. The page does not clearly print every plan's checkout total, so confirm the amount charged upfront. The subscription includes telehealth visits, unlimited provider messaging, ongoing clinical care, app tools, and eligible lab work, but not medication. Sesame says brand-name GLP-1 drugs start at $149 per month without insurance, while the actual pharmacy cost depends on product, dose, coverage, and savings-program eligibility. Providers can help with prior-authorization paperwork, but Sesame does not bill insurance for the care subscription itself. Also note a live-page inconsistency: a $199 introductory Wegovy or Ozempic injection offer remains displayed, but the same page says that promotion expired June 30, 2026. In July 2026, do not count that price as current unless Sesame or the dispensing pharmacy reconfirms it.
- $59/month requires an annual subscription
- $99 month-to-month plan renews every 28 days
- Medication and some location-dependent lab costs are additional
Medication model: brand versus compounded
Sesame's current model is centered on FDA-approved brand products rather than an included compounded drug. The program page features Wegovy tablets and pens (semaglutide), Zepbound injection formats (tirzepatide), and Foundayo tablets (orforglipron). FDA sources confirm Wegovy, Zepbound, and Foundayo have approved weight-management indications for eligible patients. Sesame also lists Ozempic, and its wider FAQ names Mounjaro, Rybelsus, and Victoza among diabetes drugs that may be associated with weight loss. Those are not interchangeable with weight-loss approval: for example, current FDA labeling lists Ozempic for type 2 diabetes and related cardiovascular and kidney outcomes, not weight loss, so use for weight loss would be off-label. Sesame explicitly states that compounded semaglutide is not currently available through the platform. That is narrower than saying Sesame offers no compounded drug of any kind, so a reader should re-check the exact product and pharmacy rather than assume. FDA also emphasizes that compounded GLP-1 drugs are not FDA-approved and do not undergo premarket review for safety, effectiveness, or quality. No drug is guaranteed; the clinician decides whether any prescription is appropriate after evaluation.
- Featured weight-management brands include Wegovy, Zepbound, and Foundayo
- Ozempic is FDA-approved for diabetes-related indications, not weight loss
- Compounded semaglutide is currently unavailable through Sesame
Pricing ledger
Pricing ledger
Price Sesame as line items, not a headline
These are the public pricing claims and checkout questions that decide whether the offer is actually comparable.
Monthly equivalent with an annual subscription; medication is excluded.
Full annual checkout charge and renewal dateThis cadence can result in approximately 13 charges per year.
Current checkout price and billing scheduleSeparate brand-medication charge; actual cost varies by drug, dose, coverage, and pharmacy.
Exact prescription price and savings eligibilityFDA-approved brand products for eligible weight-management patients; Sesame also lists Ozempic, which is not FDA-approved for weight loss.
Current formulary and prescribed indicationSource: Sesame official weight-loss program · Checked
Checked · confirm at checkout
Clinician and follow-up model
The care pathway begins with a health-history and goals intake, followed by a video consultation with a Sesame provider selected by the patient. Sesame says the clinician reviews medical history, creates a treatment plan, and may order metabolic lab testing. If treatment is clinically appropriate, the provider can prescribe a weight-loss medication and route it for home delivery or to a preferred pharmacy. The subscription advertises follow-up visits, unlimited provider messaging, refill support, and app-based tracking for weight, diet, exercise, sleep, goals, and side effects. A Sesame announcement also describes weekly app check-ins that providers can review when monitoring progress and making adjustments. This is ongoing telehealth care, not a guaranteed prescription transaction: provider discretion, contraindications, insurance rules, and pharmacy availability can all affect what happens next. Sesame says Quest Diagnostics lab work is included except in Arizona, Hawaii, North Dakota, New Jersey, New York, Oklahoma, Rhode Island, South Dakota, and Wyoming, where lab fees are additional. Because providers on the marketplace may set different prices, confirm that the clinician chosen at checkout participates at the advertised subscription rate and clarify how often live follow-ups are expected.
- Patient chooses a provider for the initial video assessment
- Follow-up visits, unlimited messaging, and weekly app check-ins are advertised
- Prescribing remains subject to the clinician's judgment
The check we would not skip
The $59 headline is a care-only annual-plan equivalent, not the complete monthly treatment cost.
How to verify before paying
Before paying, verify four separate layers. First, confirm the care contract: the total charged today, commitment length, renewal date, whether the $59 figure requires one annual payment, and the cancellation and refund deadline. The month-to-month option renews every 28 days, which can mean thirteen charges in roughly a year. Second, confirm the prescription: exact brand, active ingredient, formulation, dose, FDA-approved indication, and whether any proposed use is off-label. Third, confirm fulfillment: dispensing pharmacy, cash price or insurance copay, prior-authorization status, manufacturer-program eligibility, shipping fees, refrigeration handling for injections, and the price after any introductory period. Sesame's expired $199 Wegovy/Ozempic terms show why a price tile alone is insufficient. Fourth, confirm location rules. Sesame says licensed telehealth providers are available across all 50 states, but its weight-program page does not publish a simple current state-by-state eligibility table. Provider licensure, pharmacy shipping, and Quest lab coverage still vary by location. Ask for the full expected first charge and ongoing recurring total in writing, and verify compounded-versus-brand status from the prescription label and dispensing pharmacy, not merely from the active ingredient name.
- Capture the checkout total and renewal schedule
- Confirm the exact product, indication, pharmacy, and ongoing price
- Verify provider, pharmacy, and lab availability for the patient's state
Who it fits and who it does not
Sesame fits people who want a continuing relationship with a licensed telehealth clinician, the ability to choose a provider, ongoing video care and messaging, and access to multiple FDA-approved brand GLP-1 options. It may be especially attractive to someone with insurance coverage for the medication, or a self-pay patient willing to compare manufacturer and pharmacy programs separately. The $59 monthly equivalent can make the clinical-care layer look economical for a person comfortable with an annual commitment, and included Quest lab work adds value in most states. It is a weaker fit for someone seeking one predictable, all-inclusive monthly charge, because the medication is a second bill and may cost much more than the care subscription. It also does not currently fit someone specifically seeking compounded semaglutide, and it cannot promise that a clinician will prescribe a preferred drug or that insurance will approve it. People who dislike prepayment may prefer the $99 month-to-month option, but should account for its 28-day billing cycle. It is also less convenient in the nine listed states where Quest lab costs are excluded. Anyone needing in-person examination or more complex obesity care should confirm whether telehealth alone is appropriate before enrolling.
- Good fit for brand-focused, clinician-led telehealth care
- Poor fit for shoppers expecting medication inside one fixed price
- No prescription or insurance approval is guaranteed
Nearby options
Side-by-side
Compare Sesame against nearby options
Use this as a shortlist, not a final ranking. The right choice still depends on your quote, medication route, insurance result and follow-up needs. All comparison pages.
| Provider | Advertised cost | Medication path |
|---|---|---|
| SesameCurrent review · Score 3.9/5 | From $59/mo Source: Sesame official weight-loss program · Checked Checked · confirm at checkout | FDA-approved brand access |
| TrimRxScore 4.1/5 | From $199/mo Source: TrimRx homepage · Checked Checked · confirm at checkout | Compounded GLP-1 |
| Hims + HersScore 4.2/5 | From $149/mo meds + membership Source: Hims weight loss page · Checked Checked · confirm at checkout | FDA-approved brand paths |
| RoScore 4.3/5 | $39 first month; meds separate Source: Ro pricing page · Checked Checked · confirm at checkout | Brand GLP-1 + insurance support |
Educational content only. Do not use this page as medical advice or as a substitute for a licensed clinician, pharmacist or insurer reviewing your situation.
Related checks
Sources and what to verify (7)
Sources
- Sesame official weight-loss program
Current care pricing, separate medication charges, featured drugs, billing cadence, care model, lab exclusions, and promotion expiration.
- Sesame official semaglutide page
States that compounded semaglutide is not currently available through Sesame.
- Sesame Success program announcement
Program inclusions, provider choice, clinical oversight, and weekly app check-ins.
- Sesame telehealth availability page
Sesame's general statement that licensed healthcare providers are available in all 50 states.
- FDA Foundayo approval
Confirms FDA approval of Foundayo for long-term weight reduction in eligible adults.
- FDA Wegovy tablet approval letter
Confirms approval of oral Wegovy for adult long-term weight reduction.
- FDA Zepbound approval
Confirms Zepbound's chronic weight-management approval.